Highest-materiality recent filing
Arbutus Q1 net income $169.7M ($0.88/share) on $179.1M revenue from Moderna settlement
Revenue $179.1M up from $1.8M YoY; $178.7M license revenue from Genevant related to Moderna settlement.
Arbutus receives FDA Fast Track designation for imdusiran in chronic hepatitis B
FDA granted Fast Track designation for imdusiran, an investigational therapy for chronic hepatitis B.
Arbutus reports FY2025 results; Moderna settlement $950M; two more imdusiran functional cures
Cash, equivalents and marketable securities $91.5M at Dec 31, 2025 vs $122.6M at Dec 31, 2024.
Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026
Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.
Arbutus wins partial summary judgment in Moderna patent case; enablement goes to trial
Court bars Moderna's obviousness defense: IPR estoppel applies to '435 Patent, issue preclusion bars routine-optimization and phospholipid-range arguments.
Arbutus patent case vs Moderna to proceed in Delaware; Section 1498 defense limited
Court denies Moderna's summary judgment on Section 1498 for most vaccine doses; only government employee doses go to Court of Federal Claims.
EPO revokes Arbutus' European patent EP 2279254; company plans appeal
EPO Board of Appeal revoked Arbutus' European patent EP 2279254 on Jan 15, 2026; verbal decision without reasons; written decision expected in months.
Arbutus updates LNP litigation; Moderna trial March 2026, Pfizer/BioNTech awaits scheduling
Global COVID-19 vaccine sales since launch total ~$145BN between Moderna and Pfizer/BioNTech.
Arbutus Q3 net loss $7.7M ($0.04/sh); cash $93.7M; imdusiran data positive
Net loss of $7.7M ($0.04 per share) vs $19.7M ($0.10) in Q3 2024.
Court adopted Arbutus's proposed construction for 'fully encapsulated' as 'contained inside' in five LNP patents.
Arbutus Q2 net income $2.5M; revenue $10.7M; Dr. Sawhney joins Board
Q2 net income of $2.5M ($0.01 per share) vs loss of $19.8M in Q2 2024; total revenue $10.7M, up from $1.7M.
Arbutus reports Q1 net loss $24.5M; imdusiran functionally cures 8 cHBV patients
Net loss $24.5M ($0.13/share) vs $17.9M ($0.10) in Q1 2024; revenue $1.8M vs $1.5M.
Arbutus presents HBV functional cure data from imdusiran combo; AB-101 safety at EASL 2025
In Phase 2a IM-PROVE II, imdusiran + VTP-300 + low-dose nivolumab led to 15.3% functional cure rate (2/13) in patients with baseline HBsAg <1000 IU/mL.
Arbutus reports FY2024 net loss $69.9M; cuts workforce 57%, appoints new CFO
Net loss for 2024 was $69.9M ($0.38/share) vs $72.8M ($0.44) in 2023; revenue $6.2M down from $18.1M.
Agreement entitles Arbutus to damages specifically allocated to Moderna's mRESVIA in pending U.S. litigation; if no allocation, parties discuss in good faith.
Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign
All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.
Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M
Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.
Arbutus reports 50% functional cure in HBsAg<1000 IU/mL patients with imdusiran + IFN in Phase 2a
Cohort A1: 50% (3/6) functional cure in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; overall 25% (3/12).
Arbutus Q3 net loss $19.7M; imdusiran/AB-101 data upcoming; cash into Q4 2026
Net loss $19.7M ($0.10 per share) vs $20.1M prior year; revenue fell to $1.3M from $4.7M on lower license and royalty income.
Arbutus and Moderna agree to extend patent trial schedule to Sept 2025
Arbutus, Genevant filed stipulation with Moderna extending case schedule in COVID-19 vaccine patent suit.
Arbutus Q2 net loss $19.8M; cuts workforce 40%, extends cash runway to Q4 2026
Net loss of $19.8M ($0.11 loss per share) vs $17.1M loss prior year; revenue $1.7M down from $4.7M.
Arbutus announces positive Phase 2a data for imdusiran + VTP-300 in chronic HBV
Imdusiran + VTP-300 achieved statistically significant (p<0.05) lower HBsAg at 24 weeks post-EOT vs placebo.
Arbutus Phase 2a: imdusiran+IFN yields sustained undetectable HBsAg in 33% at 24 weeks
33.3% (4/12) on 48wk imdusiran + 24wk IFN had undetectable HBsAg at EOT, sustained 24wk post-treatment.
Arbutus presents imdusiran data at EASL: 28% achieve HBsAg loss
Two abstracts on imdusiran (AB-729) accepted for poster and oral presentations at EASL Congress 2024 (June 5-8, Milan).
Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026
Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.
Arbutus Biopharma Announces Claim Construction Ruling in Patent Lawsuit Against Moderna
Court agreed with Arbutus and Genevant that the claimed mol. % ranges for total lipid ('069 patent) are not limited to 'finished' particles and include standard variation.
Arbutus Biopharma reports FY2023 net loss of $72.8M; cash runway into Q1 2026
Net loss $72.8M ($0.44/sh) vs $69.5M ($0.46/sh) in FY2022; revenue fell to $18.1M from $39.0M.
Preliminary data from AB-729-202 trial: 97% of imdusiran-treated pts had HBsAg <100 IU/mL at first VTP-300 dose.
Arbutus Biopharma CEO William Collier to retire Dec 31; COO McElhaugh named interim CEO
William H. Collier retires as President, CEO, and director effective Dec 31, 2023.
Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire
Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.
Discontinuing AB-161 (oral RNA destabilizer) due to pre-clinical toxicology finding; no safety issues in Phase 1 single doses.
Arbutus Q2 revenue $4.7M, net loss $17.1M; AB-101 clears NZ regulatory for Phase 1
Total revenue $4.7M vs $14.2M YoY on lower Qilu license revenue; net loss $17.1M ($0.10 EPS).
Arbutus reports preliminary AB-729 + IFN data at EASL; HBsAg declines seen
Mean HBsAg decline of 1.6 log10 at week 24 during AB-729 lead-in phase.
the Company terminated, without cause, Karen Sims, M.D., Ph.D. as Chief Medical Officer of the Company, effective March 25, 2025.
the Company terminated, without cause, David Hastings as Chief Financial Officer of the Company, effective as of the end of the day on March 27, 2025.
Daniel Burgess
Ms. Androski, as Chief Executive Officer of the Company, will not receive compensation for her service as a director.
James Meyers
Richard C. Henriques
Frank Torti, M.D., chairperson of the Board
Melissa V. Rewolinski, Ph.D.
Keith Manchester, M.D.
appointed Ms. Androski as chairperson of the Board
Michael J. McElhaugh
As previously disclosed, Michael J. Sofia announced his retirement as Chief Scientific Officer of Arbutus Biopharma, Inc. (the “Company”), a subsidiary of Arbutus Biopharma Corporation, effective December 31, 2024.
Max materiality 0.90 · Median 0.65 · Most common event other_material